Combination Strategy May Optimize Interferon-based Therapy For Chronic Hepatitis B

Background and objectives

Peginterferon-α curen exhibits debased rates of nan serological conversion complaint of hepatitis B e antigen (HBeAg) and nan antagonistic conversion complaint of hepatitis B microorganism (HBV) DNA, pinch important myelosuppression starring to curen discontinuation successful immoderate patients. Traditional Chinese medicine (TCM) whitethorn ameliorate liver inflammation and modulate immune responses. This study intends to analyse nan efficacy of combining TCM pinch pegylated-interferon (PEG-IFN) α-2b and its effect connected myelosuppression adverse effects.

Methods

This study included 117 HBeAg-positive chronic hepatitis B (CHB) patients who started first antiviral therapy astatine Xiamen Hospital of TCM betwixt June 2018 and January 2023. According to nan curen regimen, patients were divided into nan study group (n = 56, receiving PEG-IFN α-2b mixed pinch Licorice 15 g, Angelica sinensis 20 g, Poria 20 g, Paeonia lactiflora 20 g, Rhizoma Atractylodis Macrocephalae 20 g, Radix Bupleurum Chinense 20 g, Mentha piperita 3 g, Ginger 3 slices for much than six months) and nan power group (n = 61, receiving PEG-IFN α-2b alone). This study retrospectively analyzed etiological indicators, liver biochemical indicators, and humor regular tests earlier and aft treatment.

Results

After 24 and 48 weeks of treatment, nan study group demonstrated importantly superior outcomes to nan power group successful quantitative simplification of hepatitis B aboveground antigen, nan serological conversion complaint of HBeAg, and nan simplification successful HBV DNA quantification (P < 0.05). By week 48, nan HBV DNA antagonistic conversion complaint successful nan study group (46.67%) was importantly higher than that successful nan power group (26.67%) (P < 0.05). Regarding safety, nan incidence of myelosuppression successful nan study group was importantly little than that successful nan power group astatine some 24 and 48 weeks of curen (P < 0.05)

Conclusions

Real-world findings show that adjunctive TCM importantly enhances nan antiviral efficacy of peginterferon α-2b successful HBeAg-positive CHB patients while concurrently mitigating treatment-limiting myelosuppression. This operation strategy whitethorn correspond a clinically valuable attack to optimizing interferon-based therapy for CHB.